Anti-BCMA CAR T-Cell Therapy for Relapsed/Refractory Immune Thrombocytopenia
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- ITP
- Sponsor
- The First Affiliated Hospital of Soochow University
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- overall response
- Last Updated
- 4 years ago
Overview
Brief Summary
This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy（BCMA CAR-T）for patients with relapse/refractory Immune thrombocytopenia(R/R ITP).
Detailed Description
Immune thrombocytopenia (ITP) is a disorder that can lead to easy or excessive bruising and bleeding. Approximately two-thirds of patients achieve remission after/during first-line therapies. However, the other part of patients could not achieve durable remission or even refractory to initial treatments. Those cases, known as relapse/refractory Immune thrombocytopenia (R/R ITP), undergo the heavy burden of disease which decreases the quality of life. Lots of pathogeneses take part in the occurrence of R/R ITP, and the most important one of them is antibody-mediated immune platelet destruction. As far as it is known，human platelet autoantibodies are mainly secreted by plasma cells, especially long-lived plasma cells. Researchers want to explore that can BCMA CAR-T help R/R ITP patients increase platelet count, reduce bleeding episodes and the dose of concomitant medications.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Refractory ITP defined according to the recent consensual criteria ( 'Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)'), or relapse ITP defined as ITP patients who have responded to first-line therapy (glucocorticoids or immunoglobulins) and anti-CD20 monoclonal antibody, but cannot maintain the response.
- •Ages 18-65 years inclusive.
- •Adequate venous access for apheresis or venous blood and no other contraindications for leukocytosis.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Subjects should have full capacity for civil conduct, understand necessary information，sign the informed consent form voluntarily，and have good corporation with the content of this research protocol.
Exclusion Criteria
- •Secondary ITP.
- •Patients with a known history or prior diagnosis of arterial thrombosis (such as cerebral thrombosis, myocardial infarction, etc.), or comorbidity of venous thrombosis (such as deep vein thrombosis, pulmonary embolism), or are using anticoagulant/antiplatelet drug at the beginning of trial.
- •Patients with a known history or prior diagnosis of serious cardiovascular disease.
- •Patients with uncontrolled infection, organ dysfunction or any uncontrolled active medical disorder that would preclude participation as outlined.
- •Patients with malignancy or history of malignancy.
- •Failed T cell expansion test.
- •During screening, hemoglobin \<100g/L; absolute value of neutrophil count \<1.5×10\^9/L.
- •During screening, serum creatinine concentration \> 1.5x the upper limit of the normal range, total bilirubin \> 1.5x the upper limit of the normal range, alanine aminotransferase and aspartate aminotransferase \> 3x the upper limit of the normal range, Left ventricular ejection fraction ≤ 50% by echocardiography, Pulmonary function ≥ grade 1 dyspnea (CTCAE v5.0), blood oxygen saturation\<91% without oxygen inhalation.
- •Prothrombin time (PT) or prothrombin time-international normalized ratio (PT-INR) or activated partial thromboplastin time (APTT) exceeding 20% of the normal reference range; or a history of coagulation abnormalities other than ITP.
- •Either HIV antibody or syphilis antibody is positive; hepatitis C antibody is positive and the detection of HCV-RNA exceeds the laboratory test upper reference limit; hepatitis B surface antigen is positive and the detection of HBV-DNA exceeds the laboratory test upper reference limit.
Outcomes
Primary Outcomes
overall response
Time Frame: 6-months
The number of participants who achieved CR (defined as platelet count≥100x10e9/L) and PR (defined as platelet count ≥30x10e9/L and at least a 2-fold increase the baseline count and absence of bleeding) at follow-up.
Secondary Outcomes
- Evaluation of bleeding events(6-months)
- Incidence of adverse events(6-months)
- Evaluation of concomitant therapy(6-months)
- Evaluation of health-related quality of life(6-months)
- Time to response(6-months)
- Duration of response(6-months)